BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 11055896)

  • 1. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.
    Bellus GA; Spector EB; Speiser PW; Weaver CA; Garber AT; Bryke CR; Israel J; Rosengren SS; Webster MK; Donoghue DJ; Francomano CA
    Am J Hum Genet; 2000 Dec; 67(6):1411-21. PubMed ID: 11055896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.
    Tavormina PL; Bellus GA; Webster MK; Bamshad MJ; Fraley AE; McIntosh I; Szabo J; Jiang W; Jabs EW; Wilcox WR; Wasmuth JJ; Donoghue DJ; Thompson LM; Francomano CA
    Am J Hum Genet; 1999 Mar; 64(3):722-31. PubMed ID: 10053006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.
    Bellus GA; Bamshad MJ; Przylepa KA; Dorst J; Lee RR; Hurko O; Jabs EW; Curry CJ; Wilcox WR; Lachman RS; Rimoin DL; Francomano CA
    Am J Med Genet; 1999 Jul; 85(1):53-65. PubMed ID: 10377013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
    Manickam K; Donoghue DJ; Meyer AN; Snyder PJ; Prior TW
    Am J Med Genet A; 2014 Jan; 164A(1):243-50. PubMed ID: 24352917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online.
    Grigelioniené G; Hagenäs L; Eklöf O; Neumeyer L; Haereid PE; Anvret M
    Hum Mutat; 1998; 11(4):333. PubMed ID: 10215410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online.
    Kitoh H; Brodie SG; Kupke KG; Lachman RS; Wilcox WR
    Hum Mutat; 1998; 12(5):362-3. PubMed ID: 10671061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.
    Iwata T; Li CL; Deng CX; Francomano CA
    Hum Mol Genet; 2001 Jun; 10(12):1255-64. PubMed ID: 11406607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia.
    Hyland VJ; Robertson SP; Flanagan S; Savarirayan R; Roscioli T; Masel J; Hayes M; Glass IA
    Am J Med Genet A; 2003 Jul; 120A(2):157-68. PubMed ID: 12833394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3-related condition: a skeletal dysplasia with similarities to thanatophoric dysplasia and SADDAN due to Lys650Met.
    Farmakis SG; Shinawi M; Miller-Thomas M; Radmanesh A; Herman TE
    Skeletal Radiol; 2015 Mar; 44(3):441-5. PubMed ID: 25119967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
    van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
    Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
    Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
    Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of thanatophoric dysplasia type I (R248C) and hypochondroplasia (N540K) mutations in two patients with achondroplasia phenotype.
    Camera G; Baldi M; Strisciuglio G; Concolino D; Mastroiacovo P; Baffico M
    Am J Med Genet; 2001 Dec; 104(4):277-81. PubMed ID: 11754059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).
    Rousseau F; el Ghouzzi V; Delezoide AL; Legeai-Mallet L; Le Merrer M; Munnich A; Bonaventure J
    Hum Mol Genet; 1996 Apr; 5(4):509-12. PubMed ID: 8845844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia.
    Grigelioniené G; Eklöf O; Laurencikas E; Ollars B; Hertel NT; Dumanski JP; Hagenäs L
    Acta Paediatr; 2000 Sep; 89(9):1072-6. PubMed ID: 11071087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.
    Vajo Z; Francomano CA; Wilkin DJ
    Endocr Rev; 2000 Feb; 21(1):23-39. PubMed ID: 10696568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
    Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
    Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
    Adar R; Monsonego-Ornan E; David P; Yayon A
    J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
    Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
    Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.